Détail d'une personne de l'annuaire - fr | Cancéropôle Est, la recherche innovante dans la lutte contre le cancer

Targeting two radiation-induced immunosuppressive pathways to improve the efficacy of normofractionated radiation therapy in a preclinical colorectal cancer model.

Boustani J, Lecoester B, Baude J, Latour C, Limagne E, Ladjohoulou R, Morgand V, Froidurot L, Ghiringhelli F, Truc G, Adotévi O, Mirjolet C

Int J Radiat Biol. 2024 03 20;:1-10

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.

Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C

BMC Cancer. 2023 11 9;23(1):1080

Protocol for simultaneous analysis of peripheral and intratumoral lymphocyte function by flow cytometry.

Daumoine S, Hampe L, Limagne E, Ghiringhelli F, Thibaudin M

STAR Protoc. 2023 10 31;4(4):102658

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.

Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derangère V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F

Nat Med. 2023 08 10;:

Combining radiotherapy and NK cell-based therapies: The time has come.

Baude J, Limagne E, Ladjohounlou R, Mirjolet C

Int Rev Cell Mol Biol. 2023 03 24;378:31-60

Simultaneous isolation of CD45 tumor-infiltrating lymphocytes, tumor cells, and associated fibroblasts from murine breast tumor model by MACS.

Kalfeist L, Petit S, Galland L, Ghiringhelli F, Ladoire S, Limagne E

STAR Protoc. 2023 01 18;4(1):101951

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.

Barnestein R, Galland L, Kalfeist L, Ghiringhelli F, Ladoire S, Limagne E

Oncoimmunology. 2022 09 13;11(1):2120676

Downregulation of Elovl5 promotes breast cancer metastasis through a lipid-droplet accumulation-mediated induction of TGF-β receptors.

Kieu TL, Pierre L, Derangère V, Perrey S, Truntzer C, Jalil A, Causse S, Groetz E, Dumont A, Guyard L, Arnould L, de Barros JP, Apetoh L, Rébé C, Limagne E, Jourdan T, Demizieux L, Masson D, Thomas C, Ghiringhelli F, Rialland M

Cell Death Dis. 2022 09 2;13(9):758

Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects.

Mary R, Chalmin F, Accogli T, Bruchard M, Hibos C, Melin J, Truntzer C, Limagne E, Derangère V, Thibaudin M, Humblin E, Boidot R, Chevrier S, Arnould L, Richard C, Klopfenstein Q, Bernard A, Urade Y, Harker JA, Apetoh L, Ghiringhelli F, Végran F

Cancer Immunol Res. 2022 05 25;:OF1-OF17

Mitophagy: a new actor in the efficacy of chemo-immunotherapy.

Limagne E, Ghiringhelli F

Autophagy. 2022 May 9;:1-2

Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer.

Thibaudin M, Limagne E, Hampe L, Ballot E, Truntzer C, Ghiringhelli F

Cancer Immunol Immunother. 2022 Mar 16;:

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era.

Kalfeist L, Galland L, Ledys F, Ghiringhelli F, Limagne E, Ladoire S

Cells. 2022 Feb 22;11(5):

MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.

Limagne E, Nuttin L, Thibaudin M, Jacquin E, Aucagne R, Bon M, Revy S, Barnestein R, Ballot E, Truntzer C, Derangère V, Fumet JD, Latour C, Rébé C, Bellaye PS, Kaderbhaï CG, Spill A, Collin B, Callanan MB, Lagrange A, Favier L, Coudert B, Arnould L, Ladoire S, Routy B, Joubert P, Ghiringhelli F

Cancer Cell. 2022 Jan 17;:

The GRP94 Inhibitor PU-WS13 Decreases M2-like Macrophages in Murine TNBC Tumors: A Pharmaco-Imaging Study with Tc-Tilmanocept SPECT.

Bouchard A, Sikner H, Baverel V, Garnier AR, Monterrat M, Moreau M, Limagne E, Garrido C, Kohli E, Collin B, Bellaye PS

Cells. 2021 12 2;10(12):

Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives.

Ledys F, Kalfeist L, Galland L, Limagne E, Ladoire S

Cancers (Basel). 2021 Nov 29;13(23):

infection has a detrimental impact on the efficacy of cancer immunotherapies.

Oster P, Vaillant L, Riva E, McMillan B, Begka C, Truntzer C, Richard C, Leblond MM, Messaoudene M, Machremi E, Limagne E, Ghiringhelli F, Routy B, Verdeil G, Velin D

Gut. 2021 Jul 12;:

Impact of proton therapy on antitumor immune response.

Mirjolet C, Nicol A, Limagne E, Mura C, Richard C, Morgand V, Rousseau M, Boidot R, Ghiringhelli F, Noel G, Burckel H

Sci Rep. 2021 Jun 29;11(1):13444

Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer.

Klopfenstein Q, Derangère V, Arnould L, Thibaudin M, Limagne E, Ghiringhelli F, Truntzer C, Ladoire S

J Immunother Cancer. 2021 06;9(6):

Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.

Medjebar S, Truntzer C, Perrichet A, Limagne E, Fumet JD, Richard C, Elkrief A, Routy B, Rébé C, Ghiringhelli F

Oncoimmunology. 2020 Oct 27;9(1):1836766

Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy.

Fumet JD, Limagne E, Thibaudin M, Ghiringhelli F

Cancers (Basel). 2020 Sep 16;12(9):

Immunological features of coronavirus disease 2019 in patients with cancer.

Thibaudin M, Fumet JD, Bon M, Hampe L, Limagne E, Ghiringhelli F

Eur. J. Cancer. 2020 Sep 7;139:70-80

and impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response.

Laurent PA, Kownacka A, Boidot R, Richard C, Limagne E, Morgand V, Froidurot L, Bonin C, Aubignac L, Ghiringhelli F, Créhange G, Mirjolet C

Clin Transl Radiat Oncol. 2020 Sep;24:116-122

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable a

Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E, Ghiringhelli F

BMC Cancer. 2020 Aug 10;20(1):748

Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma.

Niogret J, Limagne E, Thibaudin M, Blanc J, Bertaut A, Le Malicot K, Rinaldi Y, Caroli-Bosc FX, Audemar F, Nguyen S, Sarda C, Lombard-Bohas C, Locher C, Carreiro M, Legoux JL, Etienne PL, Baconnier M, Porneuf M, Aparicio T, Ghiringhelli F

Cancers (Basel). 2020 May 31;12(6):

Heat shock and HSP70 regulate 5-FU-mediated caspase-1 activation in myeloid-derived suppressor cells and tumor growth in mice.

Pilot T, Fratti A, Thinselin C, Perrichet A, Demontoux L, Limagne E, Derangère V, Ilie A, Ndiaye M, Jacquin E, Garrido C, Ghiringhelli F, Chalmin F, Rébé C

J Immunother Cancer. 2020 May;8(1):

Red Wine Extract Disrupts Th17 Lymphocyte Differentiation in a Colorectal Cancer Context.

Chalons P, Courtaut F, Limagne E, Chalmin F, Cantos-Villar E, Richard T, Auger C, Chabert P, Schini-Kerth V, Ghiringhelli F, Aires V, Delmas D

Mol Nutr Food Res. 2020 Apr 18;:e1901286

Immune Th17 lymphocytes play a critical role in the multiple beneficial properties of resveratrol.

Delmas D, Limagne E, Ghiringhelli F, Aires V

Food Chem. Toxicol.. 2019 Dec 26;:111091

Trifluridine/tipiracil plus oxaliplatin improves PD-1 blockade in colorectal cancer by inducing immunogenic cell death and depleting macrophages.

Limagne E, Thibaudin M, Nuttin L, Spill A, Dérangère V, Fumet JD, Amellal N, Peranzoni E, Cattan V, Ghiringhelli F

Cancer Immunol Res. 2019 Oct 14;:

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.

Grapin M, Richard C, Limagne E, Boidot R, Morgand V, Bertaut A, Derangere V, Laurent PA, Thibaudin M, Fumet JD, Crehange G, Ghiringhelli F, Mirjolet C

J Immunother Cancer. 2019 Jun 25;7(1):160

Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale.

Ledys F, Derangère V, Réda M, Guion JF, Milliex R, Roux V, Limagne E, Arnould L, Bengrine L, Ghiringhelli F, Rébé C

Adv Ther. 2019 Apr 12;:

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients.

Limagne E, Richard C, Thibaudin M, Fumet JD, Truntzer C, Lagrange A, Favier L, Coudert B, Ghiringhelli F

Oncoimmunology. 2019 ;8(4):e1564505

The combination of trifluridine/tipiracil and oxaliplatin induces immunogenic cell death in microsatellite stable colorectal cancer.

Ghiringhelli F, Limagne E, Thibaudin M, Nuttin L, Spill A, Derangere V, Cattan V, Peranzoni E, Amellal N

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii186

Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance.

Cotte AK, Aires V, Fredon M, Limagne E, Derangère V, Thibaudin M, Humblin E, Scagliarini A, de Barros JP, Hillon P, Ghiringhelli F, Delmas D

Nat Commun. 2018 01 22;9(1):322

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study.

Isambert N, Hervieu A, Rébé C, Hennequin A, Borg C, Zanetta S, Chevriaux A, Richard C, Derangère V, Limagne E, Blanc J, Bertaut A, Ghiringhelli F

Oncoimmunology. 2018 ;7(9):e1474319

IRF8-dependent molecular complexes control the Th9 transcriptional program.

Humblin E, Thibaudin M, Chalmin F, Derangère V, Limagne E, Richard C, Flavell RA, Chevrier S, Ladoire S, Berger H, Boidot R, Apetoh L, Végran F, Ghiringhelli F

Nat Commun. 2017 Dec 12;8(1):2085

Antibiotic Use Does Not Appear to Influence Response to Nivolumab.

Kaderbhai C, Richard C, Fumet JD, Aarnink A, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R, Ghiringhelli F

Anticancer Res.. 2017 06;37(6):3195-3200

Trifluridine/Tipiracil combined to oxaliplatin sensitizes microsatellite stable colorectal cancer to anti-PD-1 blockade.

Limagne E, Nuttin L, Spill A, Thibaudin M, Derangere V, Cattan V, Bruno A, Amellal N, Ghiringhelli F

Ann. Oncol.. 2017 Jun;28 Suppl 3:iii90

Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation.

Limagne E, Thibaudin M, Euvrard R, Berger H, Chalons P, Végan F, Humblin E, Boidot R, Rébé C, Derangère V, Ladoire S, Apetoh L, Delmas D, Ghiringhelli F

Cell Rep. 2017 Apr;19(4):746-759

Immune classifications with cytotoxic CD8(+) and Th17 infiltrates are predictors of clinical prognosis in glioblastoma.

Madkouri R, Kaderbhai CG, Bertaut A, Truntzer C, Vincent J, Aubriot-Lorton MH, Farah W, Limagne E, Ladoire S, Boidot R, Derangère V, Ghiringhelli F

Oncoimmunology. 2017 ;6(6):e1321186

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer.

Kaderbhai CG, Richard C, Fumet JD, Aarnink A, Ortiz-Cuaran S, Pérol M, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R, Ladoire S, Poudenx M, Ilie M, Hofman P, Saintigny P, Ghiringhelli F

Oncoimmunology. 2017 ;6(9):e1339856

Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.

Limagne E, Euvrard R, Thibaudin M, Rébé C, Derangère V, Chevriaux A, Boidot R, Végran F, Bonnefoy N, Vincent J, Bengrine-Lefevre L, Ladoire S, Delmas D, Apetoh L, Ghiringhelli F

Cancer Res.. 2016 Sep;76(18):5241-52

Resveratrol Interferes with IL1-β-Induced Pro-Inflammatory Paracrine Interaction between Primary Chondrocytes and Macrophages.

Limagne E, Lançon A, Delmas D, Cherkaoui-Malki M, Latruffe N

Nutrients. 2016 May;8(5):

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?

Derangère V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rébé C, Ghiringhelli F

Oncotarget. 2016 Feb;7(8):9309-21

The receptor NLRP3 is a transcriptional regulator of TH2 differentiation.

Bruchard M, Rebe C, Derangere V, Togbe D, Ryffel B, Boidot R, Humblin E, Hamman A, Chalmin F, Berger H, Chevriaux A, Limagne E, Apetoh L, Vegran F, Ghiringhelli F

Nat Immunol. 2015 Aug;16(8):859-70

Induction of oxiapoptophagy on 158N murine oligodendrocytes treated by 7-ketocholesterol-, 7beta-hydroxycholesterol-, and 24(S)-hydroxycholesterol: Protective effects of alpha-tocopherol and docosahexaenoic acid (DHA; C22:6 n-3).

Nury T, Zarrouk A, Mackrill JJ, Samadi M, Durand P, Riedinger JM, Doria M, Vejux A, Limagne E, Delmas D, Prost M, Moreau T, Hammami M, Delage-Mourroux R, O'Brien NM, Lizard G

Steroids. 2015 Feb 12. pii: S0039-128X(15)00059-8

Liver X receptor beta activation induces pyroptosis of human and murine colon cancer cells.

Derangere V, Chevriaux A, Courtaut F, Bruchard M, Berger H, Chalmin F, Causse SZ, Limagne E, Vegran F, Ladoire S, Simon B, Boireau W, Hichami A, Apetoh L, Mignot G, Ghiringhelli F, Rebe C

Cell Death Differ. 2014 Dec;21(12):1914-24